The prognostic value of IDH mutations on AML prognosis is still actively being investigated, however, IDH1 mutations are generally associated with an inferior treatment outcome and IDH2 with a favorable treatment outcome (39, 40). This evidence concerns the gene IDH2 and acute myeloid leukemia.